



## Early View

Original article

# **Cystic fibrosis in South Africa: spectrum of disease and determinants of outcome**

M. Zampoli, J. Verstraete, M. Frauendorf, R. Kassanje, L. Workman, B. M. Morrow, H. J. Zar

Please cite this article as: Zampoli M, Verstraete J, Frauendorf M, *et al.* Cystic fibrosis in South Africa: spectrum of disease and determinants of outcome. *ERJ Open Res* 2021; in press (<https://doi.org/10.1183/23120541.00856-2020>).

This manuscript has recently been accepted for publication in the *ERJ Open Research*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

Copyright ©The authors 2021. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

# CYSTIC FIBROSIS IN SOUTH AFRICA: SPECTRUM OF DISEASE AND DETERMINANTS OF OUTCOME

**Authors:** Zampoli M (1,2), Verstraete J (1), Frauendorf M (3), Kassanje R (4), Workman L (1), Morrow B.M (1) and Zar HJ (1,2).

## Affiliations

1. Department of Paediatrics and Child Health, University of Cape Town
2. South African MRC Unit for Child and Adolescent Health; University of Cape Town
3. Milpark Netcare Hospital, Johannesburg, South Africa
4. Centre for Infectious Disease Epidemiology and Research (CIDER); School of Public Health and Family Medicine; University of Cape Town

## Corresponding author:

A/Prof M Zampoli  
5<sup>th</sup> floor ICH Building  
Red Cross War Memorial Children's Hospital  
Klipfontein Rd  
Rondebosch, 7700

**Telephone:** +27 21 658 5309

**E-mail address** [m.zampoli@uct.ac.za](mailto:m.zampoli@uct.ac.za)

**Funding:** Cystic Fibrosis Foundation (ZAMPOL19K0); National Research Foundation SA (UID: 117885); Harry Crossley Foundation, University of Cape Town; and SA CF Association.

## Take home message

Analysis of the recently established South African (SA) CF registry showed that MRSA and undernutrition was associated with severe CF-lung disease. Highly effective CFTR modulator therapy would benefit the majority of people with CF in SA.

## Abstract

**Introduction:** Little is known about cystic fibrosis (CF) in low-middle income settings. This study aimed to describe the spectrum and outcomes of CF in South Africa (SA) from the recently established SA CF registry (SACFR).

**Methods:** Demographic, diagnosis and clinical data was extracted from the SACFR. Cross-sectional univariable and multivariable regression analysis of best forced expiratory volume in one second (FEV<sub>1</sub>; age ≥ 6 years) and nutrition (all ages) in 2018 was conducted to investigate factors associated with severe lung disease (SLD; FEV<sub>1</sub> < -3.0 z-score) and undernutrition.

**Results:** By December 2018, ancestry of 447 individuals included in the SACFR was Caucasian (315; 70%), mixed (87; 19%) and black African (41; 9%). Median diagnosis age was 7.6 months (IQR 2.7,37.1). Genotype was p.Phe508del homozygous (220; 49%); p.Phe508del heterozygous (144; 32%) and neither p.Phe508del or unknown Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) variant in 83 (19%); the second most frequent CFTR variant was 3120+1G>A, common in black Africans. Median age of patients in 2018 was 14.7 years (IQR 7.4,24.4). SLD was independently associated with chronic *methicillin resistant S.aureus* (MRSA) (aOR 16.75; 95%CI 1.74-161.50), undernutrition (aOR 5.20; 95%CI 2.23-12.13) and age (aOR 2.23 per 10-years; 95%CI 1.50-3.31). Undernutrition was associated in univariable analysis with low weight at diagnosis, non-caucasian ancestry, chronic *P.aeruginosa* infection and lower socioeconomic status.

**Conclusion:** Interventions targeting MRSA infection and nutrition are needed to improve CF outcomes in SA. Most people with CF in SA are eligible for highly effective CFTR modulator therapy.

## Introduction

Cystic fibrosis (CF) occurs with varying frequency in all population groups throughout the world. Although CF survival has improved over the past two decades, it remains a life-shortening condition with median survival age for a person with CF in 2018 in the United States (US) approximately 47 years<sup>1</sup>. Nutrition, lung function (LF) and rate of LF decline are important predictors of CF-related morbidity and mortality<sup>2,3</sup>. Preserving LF and slowing the rate of LF decline is key to improving CF survival.

CF registries from high income countries have contributed significantly to our understanding of CF epidemiology and survival<sup>4,5</sup>. Epidemiological and longitudinal data of over 72000 people living with CF today are currently recorded in CF registries in the US, Canada, Europe, Australasia and Brazil, with coverage rates reported to be as high as 90% of the CF population<sup>5</sup>. Several known modifiable and non-modifiable factors in high income countries have been associated with lower LF and accelerated LF decline in CF<sup>6,7,8</sup>. However, it is unclear if similar or other determinants of CF lung disease exist in low- or middle-income countries (LMIC) such as South Africa (SA). Socioeconomic factors such as poverty, limited access to appropriate healthcare, CF medications and social complexity are more prevalent in LMIC and important factors associated with poor CF-related outcomes such as LF and survival<sup>9,10,11</sup>. Lower LF and survival has been documented in Hispanic CF populations in the US compared to non-Hispanics<sup>12,13</sup>. Ancestry and socio-economic status (SES) are expected to be significant determinants of CF-related outcomes in SA, which is reported to be one of the most unequal societies in the world.<sup>14</sup>

South Africa launched its CF registry in 2018 and adopted similar data collection methods as the 2017 European CF registry<sup>15</sup>. South Africa is categorised by the World Bank as a high-middle income country and has a population of nearly 60 million<sup>16</sup>. Healthcare infrastructure and services are provided to most of the population through a resource-constrained public health system and a smaller but well-resourced private healthcare system. The prevalence of Cystic Fibrosis Transmembrane Conductance Regulator (*CFTR*) mutations in the SA population and incidence of CF also varies greatly. P.Phe508del is the most common mutation amongst Caucasians (prevalence 76%), whereas 3120+1G>A the most common mutation (prevalence 46%) in black Africans<sup>17</sup>, with an estimated carrier frequency rate of 1 in 90 healthy individuals<sup>18</sup>. A review of *CFTR* mutations identified across 12 African countries (predominantly Northern Africa and South Africa) identified 70 *CFTR* mutations of which 39 were known disease-causing mutations and five novel mutations<sup>19</sup>. There is therefore an urgent need to investigate the spectrum and determinants of CF disease in the SA population, especially in non-Caucasian people. The aim of this study was to describe the spectrum of CF in SA and explore LF and nutrition outcomes captured in the SA CF registry (SACFR).

## Methods

### *Study design and population:*

A descriptive cross-sectional study was conducted using anonymised data extracted from the SACFR, a multi-centre public-private collaboration designed to collect similar data and variable definitions as per the 2017 European CF patient Registry report<sup>20</sup> and SACFR 2018 patient registry report<sup>21</sup>. The SACFR was established in 2018 and enrolls consenting adults and children receiving CF care in SA. Recruitment of CF registry participants was initiated through formation of the SACFR steering committee which represents all known CF care clinics in public and private health sectors. In addition, the SA CF Association, the local CF advocacy organisation actively promotes participation in the SACFR through its press and social media networks. Data extraction from medical records and data entry into the SACFR is performed by two qualified data managers who visit each participating site on an annual basis. Demographic, CF diagnosis and genotype information were extracted and described for all individuals diagnosed in SA up to the end of

December 2018. Annual review data for period 1 January to 31 December 2018 were extracted, including outcome variables: 1) best documented pre-bronchodilator forced expiratory volume in one second (FEV<sub>1</sub>) and; 2) accompanying weight/height (age six years and older), or best weight/height if no LF was recorded. In the event of death, the best recorded measurements in 2018 prior to dying were included in analyses. FEV<sub>1</sub> was reported as z-scores calculated with the Global Lung Initiative (GLI) ethnic-specific reference equations<sup>22</sup>. Severe lung disease (SLD) was defined as FEV<sub>1</sub>z score  $\leq -3$ <sup>23</sup>. Undernutrition for the purpose of this study was defined according to age group: World Health Organization (WHO) nutritional reference equation weight-for-height z-score (WHZ)  $< -1$  SD in children  $< 2$  years age; Body Mass Index z-score (BMI kg/m<sup>2</sup>)  $< -1.0$  in children age 2-17 years; and BMI  $< 18.5$  kg/m<sup>2</sup> in adults  $\geq 18$  years age.

#### *Modified SACFR CF diagnosis inclusion criteria and SACFR variables*

People with a confirmed diagnosis of CF were captured in the SACFR if they met the following modified SA CF diagnostic criteria:

- 1) Two sweat chloride tests  $> 60$  mmol/L or sweat conductivity  $> 90$  mmol/L and clinical features compatible with CF *or*;
- 2) DNA analysis/genotyping identified two disease-causing *CFTR* mutations as reported at the time in CFTR<sup>24</sup> database *or*
- 3) sweat chloride  $\leq 60$  mmol/L chloride and both of the following criteria are met: a) DNA analysis/genotyping identified two disease-causing *CFTR* mutations; *and* b) clinical presentation consistent with typical or atypical CF or a CF-related disorder (CFRD)<sup>25</sup>. People diagnosed with a CFRD were included the SACFR.

Additional variables added to the SACFR included: composite measures of SES (e.g. public or private health care, reliance on public transport; household amenities and receipt of social welfare grants); other infections including *Haemophilus influenzae*, *methicillin resistant staphylococcus aureus* (MRSA), *aspergillus fumigatus*, other fungus/mould species, human Immunodeficiency virus (HIV) and *mycobacterium tuberculosis*. Chronic pulmonary infection with CF pathogens was defined by Modified Leeds criteria<sup>26</sup>. Chronic pulmonary infection status was classified as unknown if less than four respiratory samples were submitted for culture during the year or the infection status of each pathogen could not be established from past medical records.

#### *Standard of CF care in South Africa*

Multidisciplinary CF care in the public sector is provided at six CF centres located in tertiary hospitals. Individual practitioners with CF expertise provide CF care in the private sector. Essential CF care and CF medications including pancreatic enzyme replacement therapy (PERT), hypertonic saline, azithromycin and antimicrobials are freely available in the public sector, but expensive CF therapies such as inhaled tobramycin solution, recombinant DNase and organ transplantation are restricted or not available in the public sector. Private health insurance schemes in SA vary considerably in what they reimburse for CF care, ranging from basic care equivalent to the public health sector, to comprehensive care that includes reimbursement for inhaled tobramycin solution, recombinant DNase and unlimited CF investigations (e.g. sputum cultures), however, often with additional out of pocket co-payments by the members. Off-label prescription of inhaled intravenous antibiotic formulations (e.g. gentamycin, amikacin and colimycin) for treating *P. aeruginosa* infection is widely practised due to lack of affordable alternatives. Reliable sweat chloride testing or sweat conductivity testing in SA is available only in the main cities, and limited *CFTR* panel testing is available. Newborn screening for CF is not widely performed in SA and *CFTR* modulator therapy is not available in SA. South African Consensus CF guidelines were published in 2017 with recommendations for appropriate standards of CF care for the SA setting<sup>27</sup>.

## *Statistical analysis*

Data preparation and analyses were conducted in R (v3.3.3), using the glm function to fit the regression models. Descriptive statistical tests were reported for the spectrum of clinical features and therapies, using data captured in the SACFR. Reported measures of centrality and spread were guided by whether distributions are approximately normal. Groups of individuals (by ancestry or age) were compared using chi-squared or Fisher's exact (categorical variables), Kruskal-Wallis (medians of continuous variables) or ANOVA (means of continuous variables) tests. Differences in pulmonary therapies by whether SLD occurred were assessed using chi-squared tests; ANOVA was used to compare FEV1 percentage predicted (pp) means by age category; and Pearson correlation coefficients were used to relate BMI scores to FEV1z scores.

The primary outcome measure in people aged six years and older was LF; and nutrition for all ages the secondary outcome. The frequencies of these binary outcomes were analysed using univariable and multivariable logistic regression models, producing unadjusted and then adjusted Odds Ratios (aORs) for known or suspected demographic, genotype, socioeconomic, nutritional, microbiological and co-morbidity/complication risk/protective factors. To reduce the limitations posed by multiple factors considered in testing, we produced adjusted p-values for the unadjusted ORs, using Holm's method. All factors in univariable analysis are with unadjusted p-values < 0.2 are presented in tables. Variables with Holms-adjusted p-values < 0.2 in univariable analyses were included in the multivariable models, as well as the confounder age. A p-value of < 0.05 was considered statistically significant.

This study aligns with the Declaration of Helsinki 2013 and was approved by the Faculty of Health Sciences Human Research Ethics Committee, UCT (HREC R007/2018) and the SACFR Steering Committee.

## **Results**

### *Demographic and clinical characteristics at time of CF diagnosis, December 2018 (Table 1)*

By 31 December 2018, 447 individuals (235, 52.6% female) with confirmed CF diagnosis were captured in the SACFR. Twelve individuals were excluded from the study as diagnostic criteria of the SACFR was not met and one patient declined registry consent. Median age of diagnosis was 7.6 months (IQR 2.7,37.1), with 253 (56.6%) diagnosed under one year of age. Sixty-eight (15.2%) presented with neonatal bowel obstruction (any form of meconium ileus presentation diagnosed clinically and managed operatively or non-operatively), the rest were diagnosed based on symptoms or an affected sibling. Only one child whose family immigrated to SA was diagnosed in the US through newborn screening. Weight and height measurement at diagnosis was missing for 131 (31.3%) and 183 (43.7%), respectively, of 419 children diagnosed < 18 years age. The median WAZ of children at diagnosis was -2.2 (IQR -3.8, -0.9) of which 37.2% were severely underweight for age (WAZ < -3.0). Median WAZ differed significantly by ancestry ( $p < 0.001$ ) and was lower in non-Caucasian groups (-4.2 to -2.8) than Caucasians (-1.5). One hundred and eighteen (26%) patients had one sweat chloride test and 94 (23%) two; 68 (15%) had one sweat conductivity test and 34 (8%) two. At least one sweat chloride test and/or one sweat conductivity test was documented in 212 (47%) and 102 (24%) people, respectively. One hundred and fifty-two (34%) people did not have any sweat tests documented. Reasons for missing sweat test were not documented in the SACFR but include either not done or results missing from medical records.

Complete genotype diagnosis was available in 398 (89%): p.Phe508del was the most common *CFTR* variant identified in homozygous (49.2%) or heterozygous (32.2%) state. 3120+1GA was the second most common *CFTR* variant: 23 (5.1%) in homozygous and 39 (8.7%) in heterozygous state, each mostly in non-Caucasians ( $p < 0.001$ ); with 56.1% black Africans homozygous for 3120+1GA. Incomplete genotyping (one or two unknown *CFTR* variants) differed significantly by ancestry ( $p <$

0.001) with greater prevalence among those of mixed ancestry (21.8%) and black Africans (29.3%) compared to Caucasians (5.7%), table 1.

#### *General description of SACFR cohort in 2018 (n=413) (Table 2)*

Twenty people not seen in 2018 for follow-up, 10 lung transplant (three in 2018) and two liver transplant recipients were excluded from analysis. The median age of the SACFR cohort in 2018 was 14.7 years (IQR 7.4,24.4), with 242/413 (58.6%) children younger than 18 years of age. There were more non-Caucasian children (n=99, 40.9%) compared to adults (n=25, 14.6%) ( $p<0.001$ ). Except for one, all black Africans (n= 39) were less than 18 years old. One hundred and seventy-one (41.4 %) people received care exclusively in the public health sector and 242 (58.6%) received care partially or exclusively in the private health sector. Human Immunodeficiency virus testing was documented in 202 (45.2%) of which one adolescent was HIV-infected and three children were HIV-exposed, uninfected. There were three reported deaths in 2018, all in adults. Demographic, socioeconomic, nutritional, microbiological and co-morbidity/complication details are presented in table 2.

#### *Lung function and correlates of severe lung disease in 2018 (Table 2, Figure 1, Figure 2, Table 3)*

Lung function measurements in 2018 were available in 292 individuals (140 children  $\geq 6$  years and 152 adults; no LF documented n=41), table 2. The distribution of LF across age categories is shown in figure 1 with significant differences by age ( $p<0.001$ ) and a clear trend of decreasing FEV<sub>1</sub>pp with increasing age, and largest observed decline in median FEV<sub>1</sub>pp between 6-11 year (95.9pp) and 12-17 year (75.7pp) age groups.

As expected, there were significant differences between the age groups 0-6 years, 6-17 years and  $\geq 18$  years for the majority of microbiology cultures and pulmonary therapies, table 2. Comparison between children aged 6-17 years and adults  $\geq 18$  years showed that ever had ( $p<0.001$ ) and chronic *P. aeruginosa* infection ( $p<0.001$ ) and isolation of fungus or mould species ( $p=0.015$ ) was more prevalent in adults. Isolation of any *non-tuberculous mycobacteria* (NTM, 1.2% and chronic MRSA infection (6.3%) was uncommon in all ages; one child had confirmed *M. tuberculosis* infection. Classification of 'chronic infection' status for multiple pathogens was not possible in approximately *one third* of individuals due to insufficient number of sputum samples collected in the year of follow-up. Most individuals  $\geq 6$  years were receiving low-dose azithromycin; 280 (84.1%) inhaled antibiotics; 191 (57.4%) inhaled hypertonic saline 164 (49.2%) and recombinant DNase 111 (33.3%).

BMI was associated with LF, shown in figure 2: There were significantly positive correlations between BMI z-scores and FEV<sub>1</sub> z-scores in children aged 6-17 years (Pearson correlation coefficient 0.39; 95% CI: 0.24,0.52;  $p < 0.001$ ) and between BMI (kg/m<sup>2</sup>) and FEV<sub>1</sub> z-scores in adults aged  $\geq 18$  years (0.28; 95% CI: 0.13,0.42;  $p < 0.001$ ).

Twenty-six (18.6%) children and 70 adults (46.1%) had study defined SLD, of which two children (2.1%) and 23 adults (15.1%) had FEV<sub>1</sub> less than 40pp. No evidence of association was observed with SLD and receiving inhaled hypertonic saline ( $p=0.256$ ) or recombinant DNase ( $p=0.742$ ). Conversely, low dose azithromycin (98% vs. 79%;  $p < 0.01$ ) and inhaled antibiotic therapies (75.5% vs. 51.4%;  $p < 0.01$ ) were prescribed more frequently in individuals with SLD than without SLD.

Univariable ( $p < 0.2$ ) and adjusted multivariable associations with SLD are presented in table 3. Older age (aOR 2.23 per 10-year units; 95% CI 1.50,3.31) and undernutrition (aOR 5.20; 95% CI 2.23, 12.13) were independently associated with SLD, as was chronic MRSA infection (aOR 16.75; 95% CI 1.74-161.50) although there is substantial uncertainty in magnitude of the association. Chronic *P. aeruginosa* infection was associated with SLD, but the effect not significant (aOR 1.98; 95% CI 0.90, 4.34) after adjusting for other variables, table 3.

#### *Nutrition in 2018 (Table 4)*

Nutritional measurements in 2018 were available in 237 children and 161 adults, of which the majority (354, 88.9%) were pancreatic insufficient. Overall, study-defined undernutrition was present in 63 (26.6%) children and 28 (17.4%) adults.

On univariable analysis, undernutrition was associated with low WAZ at diagnosis, non-Caucasian ethnicity, 3120+1G>A genotype, chronic *P.aeruginosa* infection and indicators of low-SES: receiving public healthcare and a social welfare grant, table 4. While receiving a social welfare grant tended towards statistical significance (aOR 1.81; 95% CI 0.92-3.57), multivariable analysis did not identify any independent associations with undernutrition.

#### **Discussion**

This first comprehensive description of CF in SA highlights the importance and value of a CF registry in understanding the unique spectrum and epidemiology of CF in LMIC such as SA. Our findings highlight several important aspects which have diagnostic and therapeutic implications for future CF care in SA and other LMICs. These include ethnic-specific genotypes, limitations in areas of CF diagnosis and care, and correlating nutrition and LF outcomes. Furthermore, the higher proportion of children compared to adults, similarly observed in other LMIC such as Brazil may be the effect of lower survival age in SA compared to high income countries where adults outnumber children<sup>11</sup>. The newly established SACFR is therefore a useful tool in the long-term to prioritise and guide interventions that could improve CF outcomes in SA where median survival age in 2008 at a single centre was below 20 years age<sup>28</sup>.

The true number of people living with CF in SA is unknown. Based on *CFTR* carrier frequency rates of studies dating back to 1999, estimates of CF incidence in Caucasian, mixed race and black African populations are 1 in 3000 (carrier frequency 1 in 23), 1 in 10300 (carrier frequency 1 in 55) and 1 in 784 -13924 (carrier frequency 1 in 14 to 1 in 59 live births), respectively<sup>18,29</sup>. A national survey in 2016 reported nearly 56 million people in SA, of which the majority (45 million) were black Africans and 4.5 million Caucasian<sup>30</sup>. By extrapolation, the estimated number of children born with CF in the same generation would have been 3214 black Africans and 1500 Caucasians. There appears to be a significant discrepancy in population estimates and documented number of people with CF in all ancestries, especially black Africans. Early reports of CF in black Africans in SA and Kenya date back to 1959<sup>31,32</sup>. Since then, more studies from SA, Rwanda and Sudan have described CF in children of African ancestry with the 3120+1G>A mutation<sup>18 33 34 35 36 37</sup>. It is notable that all, but one, black Africans with CF in the SACFR are children. This may be explained in our opinion by increased awareness and diagnosis of CF in non-Caucasian people in the last decade or increased mortality in non-Caucasians before CF is diagnosed and represents an area of future research that stems from the SACFR. Cystic fibrosis expertise and diagnosis capacity are located only in a few cities across SA. It is likely that there are some people receiving care outside recognised CF care centres or practices that have not been captured in the SACFR. Furthermore, fragmented health care systems and lack of diagnostic capacity in under resourced rural provinces are factors in our experience that contribute to delayed or missed CF diagnosis in children in SA. Increased CF-related infant mortality and malnutrition in children from lower socioeconomic groups has been previously documented in SA<sup>28,37</sup>. In the absence of newborn screening, we suspect high numbers of undocumented CF-related infant deaths may be occurring in SA and incorrectly attributed to malnutrition or infectious disease, which is common in poor and rural communities. The high proportion (37%) of children in our study with severe malnutrition at the time of CF diagnosis is supportive of this hypothesis.

As expected, the genotype profile of CF in SA is closely linked to ancestry (table 1 and supplementary table 1). p.Phe508del is the most common mutation in Caucasians and people with mixed ancestry. Approximately 80% of people with CF in SA have at least one copy of p.Phe508del mutation and are therefore eligible for triple combination (elexacaftor/ivacaftor/tezacaftor) CFTR



modulator therapy. In contrast, 3120+1G>A, a class 1 minimal function mutation, was the second most common mutation in people with mixed ancestry and the most common mutation in black Africans. Importantly, incomplete or unknown genotyping was present in 11% of people, with higher prevalence observed in people with mixed ancestry and black Africans. Similar genotype profiles and increased prevalence of rare or unknown *CFTR* mutations has been reported in Brazil, a LMIC which shares demographic and socioeconomic characteristics with SA<sup>38</sup>. These findings highlight the limitation of commercial *CFTR* testing kits, which are more suited for people of European descent, and the need for LMIC to develop and adopt genotyping strategies that are more appropriate for local populations. Rare, unknown and 3120+1G>A collectively comprise nearly a third of all alleles in the SACFR population. This has implications for diagnostic strategies including newborn screening and highlights the importance of the sweat test to confirm CF diagnosis in LMIC where availability of full *CFTR* genotyping and next generation sequencing is often limited or absent and may lead to a diagnosis of CF being unconfirmed or missed. Of concern, only half of registry entries had at least one sweat chloride/sweat conductivity test documented. Furthermore, sweat conductivity was sometimes the only sweat test reported. Although sweat conductivity has been validated to diagnose CF associated with minimal function *CFTR* mutations, interpretation of intermediate conductivity reference ranges is problematic and the utility of sweat conductivity in diagnosing atypical CF or CF-related disorders is unknown<sup>39</sup>. The high number of missing sweat test results in the SACFR in our opinion is explained by either lack of access to sweat testing outside the main cities and missing results from medical records, especially in older patients. Improving documentation and accessibility to sweat chloride testing in SA is highlighted through this study as an important priority. Another implication of our findings is recognition that most black Africans, owing to the high prevalence of the 3120+1G>A mutation, will not benefit from currently licensed *CFTR* modulator therapies. Advocacy to include African people in global *CFTR* modulator drug development initiatives is another priority.

Poor LF and nutrition are important co-dependent predictors of survival in CF<sup>8</sup>. Identifying modifiable factors that preserve LF decline and improve nutrition is key to improving CF survival. After adjusting for age and factors associated with poor LF that were identified in univariable analyses, undernutrition was the strongest independent modifiable factor associated with SLD. These findings mirror difference observed with LF, nutrition and survival outcomes in Canada compared to the US. Better outcomes in Canada have been attributed to differences in childhood nutrition, access to universal free CF care and access to lung transplantation. However, LF and nutrition outcomes in the US are improving, which is attributed to introduction in the US of high-fat, high-calorie diets, newborn screening and improved access to CF health care<sup>8,40</sup>. Interventions that improve CF nutrition, particularly amongst poor communities in public health care services in SA where undernutrition is most prevalent, are therefore key to improving CF survival in SA. Newborn screening for hereditary conditions including CF is available only on request in the private sector and for a fee to the public, and therefore rarely performed in South Africa. This presents a significant barrier to improving CF outcomes in SA, especially severe malnutrition, as reported in this study, is common in SA at the time of diagnosis. Chronic *P. aeruginosa* and MRSA infections are additional modifiable factors associated with lower LF in SA, which is consistent with international observations<sup>6</sup>. Inhaled antibiotic therapies (e.g. tobramycin, aztreonam) and dry powder antibiotic formulations are either not available or very expensive relative to household income in South Africa. The average disposable household income per annum in SA is approximately 2300 USD<sup>41</sup>. The cost of one month of rDNAse and tobramycin inhalation solution is approximately three- and 10-fold the average monthly household income, respectively. Active surveillance to detect early infections and aggressive eradication protocols using effective low-cost alternate approaches such as inhalation of gentamycin intravenous solution for *P. aeruginosa* eradication can be more widely adopted throughout SA<sup>42</sup>. Our LF data must, however, be interpreted with caution due to the small number of individuals with chronic MRSA and up to a third of people with missing chronic lung infection status data because of insufficient sputum samples collected during the year of review or infrequent clinic visits. This highlights another important deficit in SA CF care needing

attention. The SACFR adopted European CF registry chronic infection status definitions in line with international CF registry harmonisation guidelines<sup>20</sup>. In our experience, factors preventing frequent sputum sampling practises in SA include fragmented health services, limited access to multidisciplinary CF care and financial constraints in people with limited or no private health insurance who need to pay out of pocket for surveillance or routine laboratory investigations.

Interpretation of the SACFR data is limited by the absence of longitudinal or retrospective data which has excluded CF-related outcomes and deaths prior to 2018, children who may have died of CF without being diagnosed or people in whom informed consent for inclusion in the registry was not yet obtained. Longitudinal cohort data captured in future by the SACFR will be helpful to establish early life determinants of LF and CF survival in South Africa. Although we estimate most people alive and diagnosed with CF are captured in the SACFR, we suspect there are still a small number of CF patients receiving care outside the recognised participating SACFR clinics and practices. In addition, several patients were excluded from the LF and nutrition analyses due to missing data which is an inherent challenge with registry data collection and analysis. Missing SACFR data is a major limitation of this study as data entry into the registry relies on relevant measurements and investigations being accurately recorded in the medical records by treating clinicians. Routine CF care and frequency of CF visits is unregulated and not standardised in SA. Private sector care is strongly influenced by individual patient financial resources and variable levels of reimbursement by private health insurers. Public sector care, which serves predominantly uninsured poorer patients, is inconsistent at different clinics and frequency of routine attendance at CF clinics is dependent on access to reliable transport and other socioeconomic factors. People with CF living in remote or rural areas infrequently attend participating CF clinics which could be another factor contributing to missing data. Missing data or incomplete information relating to CF diagnosis in older children and adults was an additional limitation.

In summary, this first comprehensive overview of CF in SA has identified important epidemiological data which is useful to guide strategies and interventions to improve CF diagnosis capacity and CF-related outcomes. Based on genotype, most people with CF in SA are eligible for highly effective CFTR modulator therapy which is currently not available in SA. Accelerating affordable access to CFTR modulator therapy and improving nutrition and treatment of MRSA and *P.aeruginosa* infections will lead to better LF outcomes in SA.

## Acknowledgements

We would like to thank the CFF, SA CF Association, Dr Michael Anstead, the Philp family and Molly McNeill Estate for their generous support.

We also acknowledge members of the SACFR steering committee as collaborators who contributed data:

Name	Affiliation
Dr Fiona Kritzinger	The Chest and Allergy Centre; Netcare Christian Barnard Memorial Hospital, Cape Town, SA.
Dr Taryn Gray	The Chest and Allergy Centre; Netcare Christian Barnard Memorial Hospital, Cape Town, SA
Dr Julie Morrison	Department of Paediatrics and Child Health, Stellenbosch University; Tygerberg Hospital, Cape Town, SA.
Prof Pierre Goussard	Department of Paediatrics and Child Health, Stellenbosch University; Cape Town , SA.
Prof Greg Calligaro	Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute and South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, SA.
Prof Paul Wilcox	UCT Private Academic Hospital, Cape Town, SA
Dr Tony Biebuyck	Panorama Medi-Clinic Hospital, Cape Town, SA
Dr Susan Klugman	Department of Paediatrics and University of Witwatersrand; Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, SA.
Dr Cathy Baird	Netcare Milpark Hospital, Johannesburg, SA
Dr Siza Sezani	Department of Paediatrics and Child Health, Faculty of Health Sciences, University of Pretoria, Pretoria, SA ; Steve Biko Academic Hospital
Prof Robin Green	Department of Paediatrics and Child Health, Faculty of Health Sciences, University of Pretoria, Pretoria, SA; Steve Biko Academic Hospital
Dr Carla Els	Netcare Linksfield Hospital, Johannesburg, SA
Dr Dave Richard	Sandton Medi-Clinic, Johannesburg, SA.
Prof Refiloe Masekela	Department of Paediatrics and Child Health, Nelson R Mandela School of Clinical Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, SA
Dr Reratilwe Mphahlele	Department of Paediatrics and Child Health, Nelson R Mandela School of Clinical Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, SA
Dr Graham Lawrence	Busamed Hillcrest Private Hospital, Durban, SA
Dr Jonathan Egner	Netcare St Augustine's, Durban, SA
Dr Paul Gebers	Netcare Greenacres Hospital and Life St. George's Hospital; Port Elizabeth, SA.

## References

1. Annual CFF registry report 2018 . Available at: <https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2018-Patient-Registry-Annual-Data-Report.pdf>; accessed 19 September 2020.
2. Corriveau S, Sykes J, Stephenson AL. Cystic fibrosis survival: the changing epidemiology. *Curr Opin Pulm Med*. 2018;24(6):574-578.
3. McColley SA, Schechter MS, Morgan WJ, Pasta DJ, Craib ML, Konstan MW. Risk factors for mortality before age 18 years in cystic fibrosis. *Pediatr Pulmonol*. 2017;52(7):909-915.
4. Fink AK, Loeffler DR, Marshall BC, Goss CH, Morgan WJ. Data that empower: The success and promise of CF patient registries. *Pediatr Pulmonol*. 2017;52(S48):S44-s51.
5. Jackson AD, Goss CH. Epidemiology of CF: How registries can be used to advance our understanding of the CF population. *J Cyst Fibros*. 2018;17(3):297-305.
6. Harun SN, Wainwright C, Klein K, Hennig S. A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis. *Paediatr Respir Rev*. 2016;20:55-66.
7. Loukou I, Moustaki M, Sardeli O, Plyta M, Douros K. Association of vitamin D status with lung function measurements in children and adolescents with cystic fibrosis. *Pediatr Pulmonol*. 2020;55(6):1375-1380.
8. Goss CH, Sykes J, Stanojevic S, Marshall B, Petren K, Ostrenga J, Fink A, Elbert A, Quon BS, Stephenson AL. Comparison of Nutrition and Lung Function Outcomes in Patients with Cystic Fibrosis Living in Canada and the United States. *Am J Respir Crit Care Med*. 2018;197(6):768-775.
9. Crowley EM, Bosslet GT, Khan B, Ciccarelli M, Brown CD. Social complexity negatively influences lung function in cystic fibrosis after transfer to adult care. *Pediatr Pulmonol*. 2020;55(1):24-26.
10. Taylor-Robinson DC, Smyth RL, Diggle PJ, Whitehead M. The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study. *Lancet Respir Med*. 2013;1(2):121-128.
11. da Silva LVRF, Zampoli M, Cohen-Cyberknoh M, Kabra SK. Cystic fibrosis in low and middle-income countries (LMIC): a view from four different regions of the world; Published ahead of print; Available at : <https://doi.org/10.1016/j.prrv.2020.07.004>; accessed 20 September 2020. *Paediatr Respir Rev* 2020.
12. McGarry ME, Neuhaus JM, Nielson DW, Ly NP. Regional variations in longitudinal pulmonary function: A comparison of Hispanic and non-Hispanic subjects with cystic fibrosis in the United States. *Pediatr Pulmonol*. 2019;54(9):1382-1390.
13. Rho J, Ahn C, Gao A, Sawicki GS, Keller A, Jain R. Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study. *Am J Respir Crit Care Med*. 2018;198(8):1055-1063.
14. Francis D, Webster E. Poverty and inequality in South Africa: critical reflections. *Development Southern Africa*. 2019;36(6):788-802.
15. Zampoli M. Cystic fibrosis: What's new in South Africa in 2019. *SAMJ: S Afr Med J*. 2019;109(1):16-19.
16. Worldometer; available at <https://www.worldometers.info/world-population/south-africa-population/>; accessed 25 April 2020.
17. Goldman A, Graf C, Ramsay M, Leisegang F, Westwood AT. Molecular diagnosis of cystic fibrosis in South African populations. *S Afr Med J*. 2003;93(7):518-519.
18. Padoa C, Goldman A, Jenkins T, Ramsay M. Cystic fibrosis carrier frequencies in populations of African origin. *J Med Genet*. 1999;36(1):41-44.
19. Stewart C, Pepper MS. Cystic fibrosis on the African continent. *Genet Med*. 2016;18(7):653-662.

20. ECFS Patient Registry Annual data report 2017. [https://www.ecfs.eu/sites/default/files/general-content-images/working-groups/ecfs-patient-registry/ECFSPR\\_Report2017\\_v1.3.pdf](https://www.ecfs.eu/sites/default/files/general-content-images/working-groups/ecfs-patient-registry/ECFSPR_Report2017_v1.3.pdf); accessed 10 January 2021.
21. Zampoli M, Verstraete J, Frauendorf M, Workman L, et al. South African Cystic Fibrosis Patient Registry Annual Report 2018;; available at : <https://www.sacfa.org.za/wp-content/uploads/SA-CF-RegistryFullReport2018.pdf>; Accessed 10 January 2021.
22. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J*. 2012;40(6):1324-1343.
23. Quanjer PH, Pretto JJ, Brazzale DJ, Boros PW. Grading the severity of airways obstruction: new wine in new bottles. *Eur Respir J*. 2014;43(2):505-512.
24. CFTR2. <https://cftr2.org/>. Accessed 25/04/2020.
25. Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, et al. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. *J Pediatr*. 2017;181s:S4-S15.e11.
26. Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. *J Cyst Fibros*. 2003;2(1):29-34.
27. The South African Cystic Fibrosis Consensus Guidelines 5th Edition. Available at [http://www.sacfa.org.za/wp-content/uploads/2017\\_09\\_14\\_CF\\_Consensus\\_Guidelines\\_2017.pdf](http://www.sacfa.org.za/wp-content/uploads/2017_09_14_CF_Consensus_Guidelines_2017.pdf); accessed 20 September 2020. 2017.
28. Westwood A. The prognosis of cystic fibrosis in the Western Cape province of South Africa: a 33 year study. Chapter 9. Doctor of Medicine thesis, University of Cape Town, 2005. 2008.
29. Westwood T, Henderson B, Ramsay M. Diagnosing cystic fibrosis in South Africa. *S Afr Med J*. 2006;96(4):304, 306.
30. Community Survey 2016 report media release 30 June 2016. Statistics South Africa. Available at : [http://www.statssa.gov.za/?p=7957&gclid=CjwKCAjwkoz7BRBPEiwAeKw3q81bwTUHmYR6Ub5OTeLgP\\_xPESMJpM2g1GrjUeqtj-Plg-V281tPShoCiKoQAvD\\_BwE](http://www.statssa.gov.za/?p=7957&gclid=CjwKCAjwkoz7BRBPEiwAeKw3q81bwTUHmYR6Ub5OTeLgP_xPESMJpM2g1GrjUeqtj-Plg-V281tPShoCiKoQAvD_BwE). accessed 18 September 2020. [press release].
31. Macdougall L. Fibrocystic disease of the pancreas in African children. *The Lancet*. 1962;280(7252):409-410.
32. Levin SE, Blumberg H, Zamit R, Schmaman A, Wagstaff L. Mucoviscidosis (cystic fibrosis of the pancreas) in Bantu twin neonates. *S Afr Med J*. 1967;41(19):482-485.
33. Masekela R, Zampoli M, Westwood AT, White DA, Green RJ, Olorunju S, Kwofie-Mensah M. Phenotypic expression of the 3120+1G>A mutation in non-Caucasian children with cystic fibrosis in South Africa. *J Cyst Fibros*. 2013;12(4):363-366.
34. Ibrahim SA, Fadl Elmola MA, Karrar ZA, Arabi AM, Abdullah MA, Ali SK, Elawad F, Ali TE, Abdulrahman MB, Ahmed SO, et al. Cystic fibrosis in Sudanese children: First report of 35 cases. *Sudan J Paediatr*. 2014;14(1):39-44.
35. Mutesa L, Azad AK, Verhaeghe C, Segers K, Vanbellinthen JF, Ngendahayo L, Rusingiza EK, Mutwa PR, Rulisa S, Koulischer L, et al. Genetic analysis of Rwandan patients with cystic fibrosis-like symptoms: identification of novel cystic fibrosis transmembrane conductance regulator and epithelial sodium channel gene variants. *Chest*. 2009;135(5):1233-1242.
36. Westwood T, Brown R. Cystic fibrosis in black patients: Western Cape experiences. *S Afr Med J*. 2006;96(4):288-289.
37. Owusu SK, Morrow BM, White D, Klugman S, Vanker A, Gray D, Zampoli M. Cystic fibrosis in black African children in South Africa: a case control study. *J Cyst Fibros*. 2020;19(4):540-545.
38. da Silva LVRF, Maróstica PJC, Athanzio RA, Reis FJC, Damaceno N, Paes AT, Hira AY, Schlesinger D, Kok F, Amaral MD. Extensive CFTR sequencing through NGS in Brazilian

individuals with cystic fibrosis: unravelling regional discrepancies in the country. *J Cyst Fibros*; published ahead of print available at: <https://doi.org/10.1016/j.jcf.2020.08.007>; accessed 19 September 2020. 2020.

39. Mattar AC, Leone C, Rodrigues JC, Adde FV. Sweat conductivity: an accurate diagnostic test for cystic fibrosis? *J Cyst Fibros*. 2014;13(5):528-533.
40. Stephenson AL, Sykes J, Stanojevic S, Quon BS, Marshall BC, Petren K, Ostrenga J, Fink AK, Elbert A, Goss CH. Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study. *Annals of internal medicine*. 2017;166(8):537-546.
41. Household disposable income in South Africa from 1990 to 2019; available at <https://www.statista.com/statistics/874035/household-disposable-income-in-south-africa/#:~:text=In%202019%2C%20South%20African%20households,about%2034%2C037%20South%20African%20Rand>; accessed 08 May 2021.
42. Van Stormbroek B, Zampoli M, Morrow BM. Nebulized gentamicin in combination with systemic antibiotics for eradicating early *Pseudomonas aeruginosa* infection in children with cystic fibrosis. *Pediatr Pulmonol* 2019;54(4):393-398.

Table 1. Demographic and clinical information, at time of diagnosis, among the CF population in South Africa, December 2018\*, stratified by ancestry.

	Caucasian n = 315	Mixed n = 87	Black African n = 41	Indian n = 4	Total n = 447
<b>Sex<sup>†</sup>: n (%)</b>	<b>n = 315</b>	<b>n = 87</b>	<b>n = 41</b>	<b>n = 4</b>	<b>n = 447</b>
Female	179 (56.8)	40 (46.0)	15 (36.6)	1 (25.0)	235 (52.6)
<b>Diagnosis age</b>	<b>n = 309</b>	<b>n = 87</b>	<b>n = 39</b>	<b>n = 4</b>	<b>n = 439</b>
Diagnosis age in months, median (IQR)	8.9 (2.0,40.0)	6.9 (2.3,26.6)	6.4 (3.5,8.9)	54.9 (4.5,130.2)	7.6 (2.7,37.1)
Diagnosis age in years: n (%)					
< 1	167 (54.0)	53 (60.9)	31 (79.5)	2 (50.0)	253 (57.6)
1-3	57 (18.4)	15 (17.2)	2 (5.1)	0 (0)	74 (16.9)
3-10	46 (14.9)	14 (16.1)	5 (12.8)	1 (25.0)	66 (15.0)
10-17	21 (6.8)	3 (3.4)	1 (2.6)	1 (25.0)	26 (5.9)
≥ 18	18 (5.8)	2 (2.3)	0 (0)	0 (0)	20 (4.6)
<b>Nutritional status</b>					
WAZ at diagnosis (age 0-17 years)	<b>n = 183</b>	<b>n = 68</b>	<b>n = 34</b>	<b>n = 3</b>	<b>n = 288</b>
Median (IQR) <sup>‡‡</sup>	-1.5 (-3.2,-0.5)	-2.8 (-4.1,1.6)	-4.2 (-5.3,-3.1)	-4.0 (-4.5,-4.0)	-2.2 (-3.8, -0.9)
WAZ < -1.0: n (%)	118 (64.5)	53 (77.9)	34 (100)	3 (100)	208 (71.9)
WAZ < -3.0: n (%)	50 (27.3)	29 (42.6)	26 (76.5)	2 (66.7)	107 (37.2)
HAZ at diagnosis (age 0-17 years)	<b>n=157</b>	<b>n=45</b>	<b>n=32</b>	<b>n=2</b>	<b>n=236</b>
Median (IQR) <sup>‡‡</sup>	-1.6 (-3.2,-0.4)	-1.8 (-3.9,-0.6)	-2.3 (-3.9,-0.6)	-1.0 (-4.0,-1.0)	-1.8 (-3.3,-0.5)
HAZ < -1.0: n (%)	102 (65.0)	31 (68.9)	24 (75.0)	1 (50.0)	158 (66.9)
HAZ < -3.0: n (%)	40 (25.5)	15 (33.3)	12 (37.5)	1 (50.0)	68 (28.8)
BMI at diagnosis in kg/m <sup>2</sup> (age ≥ 18 years)	<b>n = 6</b>	<b>n = 0</b>	<b>n = 0</b>	<b>n = 0</b>	<b>n = 6</b>
Median (IQR)	22.8 (18.6, 24.8)	-	-	-	22.8 (18.6, 24.8)
BMI < 18.5: n (%)	1 (16.7)	-	-	-	1 (16.7)
<b>Neonatal bowel obstruction: n (%)</b>	<b>n = 315</b>	<b>n = 87</b>	<b>n = 41</b>	<b>n = 4</b>	<b>n = 447</b>
Yes	57 (18.1)	8 (9.2)	3 (7.3)	0 (0)	68 (15.2)
Unknown	16 (5.1)	1 (1.1)	2 (4.9)	0 (0)	19 (4.3)
<b>Sweat Testing</b>					
Sweat chloride (mmol/L)	<b>n = 134</b>	<b>n = 62</b>	<b>n = 15</b>	<b>n = 1</b>	<b>n = 212</b>
Mean (SD)	105 (18)	107 (17)	115 (24)	109 (-)	106 (18)
Sweat conductivity in (mmol/L)	<b>n = 63</b>	<b>n = 21</b>	<b>n = 18</b>	<b>n = 0</b>	<b>n = 102</b>
Mean (SD)	104 (16)	110 (23)	105 (20)	-	106 (19)
<b>Genotype</b>					
p.Phe508del <sup>‡‡‡</sup> : n(%)	<b>n = 315</b>	<b>n = 87</b>	<b>n = 41</b>	<b>n = 4</b>	<b>n = 447</b>
Homozygous	183 (58.1)	36 (29.9)	0 (0)	1 (25.0)	220 (49.2)
Heterozygous	102 (32.4)	40 (46.0)	1 (2.4)	1 (25.0)	144 (32.2)
3120+1G>A; c.2988+1G>A <sup>‡‡‡</sup> : n(%)	<b>n = 315</b>	<b>n = 87</b>	<b>n = 41</b>	<b>n = 4</b>	<b>n = 447</b>
Homozygous	0 (0)	0 (0)	23 (56.1)	0 (0)	23 (5.1)
Heterozygous	8 (2.5)	19 (21.8)	12 (29.3)	0 (0)	39 (8.7)
Incomplete genotyping (one or two unknown <i>CFTR</i> variants) <sup>‡‡‡</sup> : n (%)	18 (5.7)	19 (21.8)	12 (29.3)	0 (0)	49 (11.0)
<b>Most common <i>CFTR</i> mutation allele frequencies<sup>#</sup>: alleles, n (%)</b>	<b>n = 630</b>	<b>n = 174</b>	<b>n = 82</b>	<b>n = 8</b>	<b>n = 894</b>
F508del; c.1521_1523delCTT/ p.Phe508del	468 (74.3)	92 (52.9)	1 (1.2)	3 (37.5)	564 (63.1)
3120+1G>A2,3; c.2988+1G>A	8 (1.3)	19 (10.9)	58 (70.7)	0 (0)	85 (9.5)
Other# (< 1 % allele frequency)	46 (7.3)	22 (12.6)	8 (9.8)	5 (62.5)	81 (9.1)
Unknown	24 (3.8)	24 (13.8)	15 (18.3)	0 (0)	63 (7.0)
3272-26A>G1; c.3140-26A>G	15 (2.4)	8 (4.6)	0 (0)	0 (0)	23 (2.6)
394delTT1; c.262_263delTT /p.Leu881IlefsX22	18 (2.9)	0 (0)	0 (0)	0 (0)	18 (2.0)
A455E; c.1364C>A / p.Ala455Glu	11 (1.7)	5 (1.7)	0 (0)	0 (0)	16 (1.8)

N1303K1; c.3909C>G / p.Asn1303Lys	10 (1.6)	0 (0)	0 (0)	0 (0)	10 (1.1)
R553X; c.1657C>T / p.Arg553X	7 (1.1)	3 (1.7)	0 (0)	0 (0)	10 (1.1)
G542X1; c.1624G>T / p.Gly542X	9 (1.4)	0 (0)	0 (0)	0 (0)	9 (1.0)
G551D; c.1652G>A / p.Gly551Asp	8 (1.3)	1 (0.6)	0 (0)	0 (0)	9 (1.0)

Legend table 1

<sup>‡</sup> and  $p < 0.05$  ,of differences in characteristic by ancestry Indicates significance <sup>\*\*\*</sup>  $p < 0.001$

\* excludes 12 people for whom diagnostic criteria of the SACFR were not met; column percentages calculated with recorded number of entries as denominator value

# Other *CFTR* mutations, supplementary table 1



Table 2. Clinical, lung function and nutritional characteristics of children and adults in the SA CF registry captured in 2018<sup>‡</sup>, stratified by age

	0-6 years	6-17 years	≥ 18 years	Total
<b>Sex: n (%)</b>	<b>n=80</b>	<b>n=162</b>	<b>n=171</b>	<b>n=413</b>
Female	40 (50.0)	87 (53.7)	94 (55.0)	221 (53.5)
<b>Age in years</b>	<b>n=80</b>	<b>n=162</b>	<b>n=171</b>	<b>n=413</b>
Median (IQR)	3.4 (2.1,5.0)	11.3(8.8,14.6)	26.9 (21.6,34.3)	14.7 (7.4,24.4)
<b>Ancestry<sup>HR</sup>: n (%)</b>	<b>n=80</b>	<b>n=162</b>	<b>n=171</b>	<b>n=413</b>
Caucasian	41 (51.3)	102 (63.0)	146 (85.4)	289 (70.0)
Mixed	19 (23.7)	38 (23.4)	24 (14.0)	81 (19.6)
Black African	20 (25.0)	19 (11.7)	1 (0.6)	40 (9.7)
Indian	0 (0)	3 (1.9)	0 (0)	3 (0.7)
<b>Pancreatic insufficient: n (%)</b>	<b>n=80</b>	<b>n=162</b>	<b>n=171</b>	<b>n=413</b>
Insufficient	75 (93.8)	144 (88.9)	146 (85.4)	365 (88.4)
<b>Socioeconomic factors</b>				
<b>Household cigarette smoke<sup>HR</sup>: n (%)</b>	<b>n=80</b>	<b>n=162</b>	<b>n=171</b>	<b>n=413</b>
Yes	13 (16.3)	39 (24.1)	8 (4.7)	60 (14.5)
<b>Receiving social welfare grant: n(%)</b>	<b>n=80</b>	<b>n=162</b>	<b>n=171</b>	<b>n=413</b>
Yes	15 (18.8)	31 (19.1)	19 (11.1)	65 (15.7)
<b>Private health insurance<sup>HR</sup>: n(%)</b>	<b>n=80</b>	<b>n=162</b>	<b>n=171</b>	<b>n=413</b>
Yes	40 (50.0)	86 (53.1)	116 (67.8)	242 (58.6)
<b>Microbiology: n (%)</b>	<b>n=80</b>	<b>n=162</b>	<b>n=171</b>	<b>n=413</b>
Age in years of 1st <i>P.aeruginosa</i> , median (IQR)	1 (0.0, 2.0)	4 (1.0, 8.0)	5 (1.0, 17.0)	3 (1.0, 9.0)
Ever had <i>P.aeruginosa</i> <sup>HR</sup> : n (%)	27 (33.8)	58 (35.8)	102 (59.6)	187 (45.3)
<b>Chronic <i>P.aeruginosa</i><sup>HR</sup>: n (%)</b>				
Yes	8 (10.0)	28 (17.3)	80 (46.8)	116 (28.1)
Unknown*	39 (48.8)	53 (32.7)	56 (32.7)	148 (35.8)
<b>Chronic MSSA<sup>HR</sup>: n (%)</b>				
Yes	6 (7.5)	40 (24.7)	26 (15.2)	72 (17.4)
Unknown*	39 (48.8)	53 (32.7)	58 (33.9)	150 (36.3)
Ever had MRSA: n (%)	2 (2.5)	15 (9.3)	9 (5.3)	26 (6.3)
<b>Chronic MRSA<sup>R</sup>: n (%)</b>				
Yes	0 (0)	7 (4.3)	7 (4.1)	14 (3.4)
Unknown*	38 (47.5)	52 (32.1)	59 (34.5)	149 (36.1)
<b>Chronic <i>B. cepacia</i><sup>R</sup>: n (%)</b>				
Yes	0 (0)	5 (3.1)	8 (4.7)	13 (3.1)
Unknown*	38 (47.5)	52 (32.1)	61 (35.7)	151 (36.6)
<b>Chronic <i>aspergillus spp</i><sup>R</sup>: n (%)</b>				
Yes	0 (0)	15 (9.3)	14 (8.2)	29 (7.0)
Unknown*	37 (46.3)	52 (32.1)	58 (33.9)	147 (35.6)
<b>Chronic <i>H. Influenzae</i><sup>R</sup>: n (%)</b>				
Yes	1 (1.3)	4 (2.5)	1 (0.6)	6 (1.5)
Unknown*	39 (48.8)	54 (33.3)	60 (35.1)	153 (37.0)
Another fungus/mould <sup>R</sup> : n (%)	12 (15.0)	26 (16.0)	45 (26.3)	83 (20.1)
Any NTM isolate: n (%)	0 (0)	2 (1.2)	3 (1.8)	5 (1.2)
<b>Pulmonary therapies: n (%) (&gt; 3 months continuous)</b>	<b>n=80</b>	<b>n=162</b>	<b>n=171</b>	<b>n=413</b>
Inhaled hypertonic saline	45 (56.3)	85 (52.5)	79 (46.2)	209 (50.6)

Recombinant DNase <sup>RR</sup>	9 (11.3)	40 (24.7)	71 (41.5)	120 (29.1)
Inhaled antibiotics <sup>RR</sup>	31 (38.8)	71 (43.8)	120 (70.2)	222 (53.8)
Low-dose azithromycin <sup>RR</sup>	47 (58.8)	127 (78.4)	153 (89.5)	327 (79.2)
<b>Complications/comorbidity): n (%)</b>	<b>n=80</b>	<b>n=162</b>	<b>n=171</b>	<b>n=413</b>
ABPA	0 (0)	8 (4.9)	10 (5.8)	18 (4.4)
CF-related diabetes <sup>RR</sup>	0 (0)	9 (5.6)	53 (31.0)	62 (15.0)
CF-related liver disease <sup>h</sup>				
With cirrhosis <sup>†</sup>	2 (2.5)	11 (6.8)	10 (5.8)	23 (5.6)
Without cirrhosis	5 (6.3)	29 (17.9)	29 (17.0)	63 (15.3)
Pneumothorax	0 (0)	1 (0.6)	1 (0.6)	2 (0.5)
Haemoptysis major (>250 ml)	1 (1.3)	5 (3.1)	1 (0.6)	7 (1.7)
Occurrence of malignancy	0 (0)	0 (0)	2 (1.2)	2 (0.5)
<b>Nutritional status</b>				
WHZ (current age 0-2 years)	<b>n=16</b>	-	-	<b>n=16</b>
Median (IQR)	-0.6 (-1.4,1.2)	-	-	-0.6 (-1.4,1.2)
WHZ <-1	7 (43.8)	-	-	7 (43.8)
BMIZ (current age 2-17 years)	<b>n=60</b>	<b>n=161</b>	-	<b>n=221</b>
Median (IQR)	0.4 (-0.4,1.1)	-0.5 (-1.1,0.4)	-	-0.3 (-1.0,0.6)
BMIZ <-1	6 (10.0)	50 (31.1)	-	56 (25.3)
BMI in kg/m <sup>2</sup> (age ≥ 18 years)			<b>n=161</b>	<b>n=161</b>
Median (IQR)			21.2 (19.2, 23.8)	21.2 (19.2,23.8)
Undernutrition <sup>#,‡</sup> : n (%)	<b>n=76</b>	<b>n=161</b>	<b>n=161</b>	<b>n=398</b>
Yes	13 (17.1)	50 (31.1)	28 (17.4)	91 (22.9)
<b>Lung function</b>	-	<b>n= 140</b>	<b>n= 152</b>	<b>n= 292</b>
FEV <sub>1</sub> pp <sup>RR</sup> : n (%)				
> 70	-	107 (76.4)	62 (40.8)	169 (57.9)
40-70	-	30 (21.4)	67 (44.1)	97 (33.2)
<40	-	3 (2.1)	23 (15.1)	26 (8.9)
FEV <sub>1</sub> pp <sup>RR</sup> : Median (IQR)	-	87.2 (71.3,102.0)	64.6 (50.1,83.1)	77.4 (58.1 91.8)
FEV <sub>1</sub> z: n (%)	-			
≤ -1.0 ; > -2.0	-	30 (21.4)	25 (16.4)	55 (18.8)
≤ -2.0 ; > -3.0	-	15 (10.7)	28 (18.4)	43 (14.7)
≤ -3.0	-	26 (18.6)	70 (46.1)	96 (32.9)
FEV <sub>1</sub> z <sup>RR</sup> : Median (IQR)	-	-1.0 (-2.4,0.1)	-2.8 (-4.0, -1.4)	-1.9 (-3.4,-0.7)

Legend table 2:

BMIZ: body mass index z-score

WHZ: weight-for-height z-score

NTM: non-tuberculous mycobacterium

FEV<sub>1</sub>z: Forced expiratory volume in one second z-score

FEV<sub>1</sub>pp: Forced expiratory volume in one second percent predicted

ABPA: allergic bronchopulmonary aspergillosis

MSSA: methicillin sensitive *S. aureus*

MRSA: methicillin resistant *S. aureus*

<sup>‡</sup> Indicates significance of differences in characteristic by age group, p<0.05 and <sup>RR</sup> p<0.001

<sup>‡</sup> excludes 20 not seen in 2018, 2 with previous liver transplants and 12 with previous lung transplants

<sup>#</sup> Undernutrition definition: World Health Organization (WHO) nutritional reference equation WHZ < -1 SD in children < 2 years age; BMI z-score (BMI kg/m<sup>2</sup>) < -1.0 children age 2-17 years; and BMI < 18.5 kg/m<sup>2</sup> in adults ≥ 18 years age.

‡ includes liver cirrhosis with portal hypertension

\*Unknown: Chronic pulmonary infection status was classified as unknown if less than four respiratory samples were submitted for culture during the year or the infection status of each pathogen could not be established from past medical records

Table 3. Unadjusted and adjusted associations with severe lung disease in children  $\geq 6$  years and adults in the SA CF registry, 2018

	Severe lung disease of FEV <sub>1</sub> z $\leq -3.0$ (n=292)				
	Univariable analysis <sup>#</sup>			Multivariable analysis (n=190)	
	n	Unadjusted OR (95% CI)	p-value	Adjusted OR (95% CI)	p-value
Neonatal bowel obstruction (ref: no)	275	0.58 (0.28,1.19)	0.126	NS	
Age diagnosis (units: 10-years)	285	1.26 (0.90,1.76)	0.180	NS	
Current age (units: 10-years)	292	1.99 (1.55,2.54)	<0.001*	2.23 (1.50,3.31)	<0.001
p.Phe508del (ref: neither record)					
Homozygous	292	0.77 (0.37,1.57)	0.069	NS	
Heterozygous	292	1.45 (0.70,3.01)			
Caucasian (ref: other ancestry)	292	1.50 (0.83,2.72)	0.171	NS	
Ever had <i>P.aeruginosa</i> (ref: no)	279	4.36 (1.65,11.49)	0.001*	1.66 (0.34, 8.12)	0.529
Time since first <i>P.aeruginosa</i> isolate (per 10-year interval) <sup>†</sup>	133	2.12 (1.38,3.25)	<0.001*	1.25 (0.85, 1.84)	0.259
Chronic <i>P.aeruginosa</i> (ref: no)	201	3.81 (2.08,6.95)	<0.001*	1.98 (0.90, 4.34)	0.088
Chronic MSSA (ref: no)	198	0.57 (0.30,1.10)	0.089	NS	
Ever had MRSA (ref: no)	261	2.46 (0.98,6.18)	0.055	NS	
Chronic MRSA (ref: no)	198	8.88 (1.89,41.73)	0.001*	16.75 (1.74, 161.50)	0.015
Other fungus or mould (ref: no)	292	2.19 (1.22,3.93)	< 0.009*	1.31 (0.58, 2.93)	0.518
ABPA (ref: no)	261	0.29 (0.06,1.30)	0.064	NS	
Household cigarette smoke exposure/ smoker (ref: no)	292	0.62 (0.30,1.28)	0.181	NS	
CF-related diabetes (ref: no)	286	3.79 (2.10,6.84)	<0.001*	1.03 (0.46, 2.33)	0.939
CF-liver disease with cirrhosis (ref: no)	282	2.87 (1.15,7.14)	0.073	NS	
Undernutrition <sup>‡</sup> (ref: no)	292	3.16 ( 1.72,5.83)	<0.001*	5.20 (2.23,12.13)	< 0.001

Legend table 3:

<sup>#</sup> All variables with unadjusted p-values <0.2 in the univariable analyses are tabulated. Refer to supplementary table 3 for full set of univariable results

\* Unadjusted p-values are shown; indicated variables had adjusted p-values < 0.2 using Holm's method and were thus included in the multivariable regression model.

<sup>†</sup> Included as an interaction term, to apply only to those who have had ever had *P.aeruginosa*

<sup>‡</sup> Undernutrition includes: WHZ < -1.0, < 2 years age; BMIz < -1.0, 2-17 years; or BMI < 18.5 kg/m<sup>2</sup>,  $\geq$  18 years

ABPA: allergic bronchopulmonary aspergillosis

MSSA: methicillin sensitive *S. aureus*

MRSA: methicillin resistant *S. aureus*

Severe lung disease: FEV<sub>1</sub>z < -3 in children  $\geq 6$  years

**Table 4.** Unadjusted and adjusted associations with undernutrition in children and adults in the SA CF registry, 2018.

	Undernutrition <sup>‡</sup> (n=398)				
	n	Univariable analysis <sup>#</sup>		Multivariable analysis (n=190)	
		Unadjusted OR (95% CI)	p-value	Adjusted OR (95% CI)	p-value
WAZ < -1.0 at diagnosis (ref: ≥ -1)	270	2.18 (1.07,4.44)	0.024*	excluded to preserve n due to large % missing	
Current age (unit: 10-years)	398	0.82 (0.66,1.01)	0.062	0.96 (0.76,1.21)	0.698
P.Phe508del (ref neither record)					
Homozygous	398	0.50 (0.27,0.92)	0.043	NS	
Heterozygous	398	0.85 (0.46,1.58)			
3120+1G>A hetero/homozygous	398	2.55 (1.42,4.58)	0.002*	1.32 (0.66,2.68)	0.438
Caucasian (ref: other ancestry)	398	0.35 (0.22,0.57)	<0.001*	0.56 (0.28,1.12)	0.100
Receiving social welfare grant (ref: no)	398	2.99 (1.70,5.25)	<0.001*	1.81 (0.92,3.57)	0.088
Private health insurance (ref: no)	398	0.46 (0.28,0.73)	<0.001*	0.87 (0.46, 1.63)	0.661
Ever had MRSA (ref: no)	351	1.86 (0.80, 4.35)	0.165	NS	
Chronic MRSA (ref: no)	255	2.31 (0.77, 6.94)	0.145	NS	
Chronic <i>P.aeruginosa</i> (ref: no)	256	1.76 (1.00,3.12)	0.050	NS	

Legend table 4:

<sup>#</sup> All variables with unadjusted p-values <0.2 in the univariable analyses are tabulated. Refer to supplementary table 4 for full set of univariable results.

\* Unadjusted p-values are shown; indicated variables had adjusted p-values < 0.2 using Holm's method and were thus included in the multivariable regression model.

<sup>‡</sup> Undernutrition includes: WHZ < -1.0, < 2 years age; BMIz < -1.0, 2-17 years; or BMI < 18.5 kg/m<sup>2</sup>, ≥ 18 years

MRSA: methicillin resistant *S. aureus*

Figure 1: FEV<sub>1</sub> percentage predicted by age category in adults and children ≥ 6 years in SA CF registry, 2018. Boxes indicate first to third quartiles, the dividing line the median, whiskers the remaining points up to length 1.5 times the IQR, and markers any remaining outliers.





Figure 2: Scatter plot of FEV<sub>1</sub> z-scores versus BMI z-scores (children aged < 18 years) or BMI measurements (adults aged ≥ 18 years) in SA CF registry, 2018, with Pearson correlation coefficients indicated.



Supplementary Table 1. *CFTR* mutation allele frequency <1% stratified by ancestry, SACFR December 2018

<i>CFTR</i> mutation allele frequencies <1%	Caucasian N= 630 n	Mixed N= 174 n	Black African N=82 n	Indian N= 8 n	Total N= 894 n (%)
W1282X1 c.3846G>A / p.Trp1282Arg	4	2	0	0	6 (0.7)
1078delT c.948delT /p.Phe316LeufsX12	4	0	0	0	4 (0.4)
R1162X c.3484C>T / p.Arg1162X	0	4	0	0	4 (0.4)
621+1G>T c.489+1G>T	2	1	0	0	3 (0.3)
Leu218X	-	1	-	2	3 (0.3)
R347H c.1040G>A / p.Arg347His	3	0	0	0	3 (0.3)
S549N c.1646G>A / p.Ser549Asn	3	0	0	0	3 (0.3)
Y563N; c.1687T>A / p.Tyr563Asn	3	-	-	-	3 (0.3)
2789+5G>A c.2657+5G>A	2	0	0	0	2 (0.2)
3849+10kbC>T1 c.3717+12191C>T	0	1	0	1	2 (0.2)
c.2738A>G / p.Tyr913Cys	2	-	-	-	2 (0.2)
CFTRdele2; c.(53+1_54-1)_(164+1_165-1)del	1	0	1	0	2 (0.2)
E60X c.178G>T / p.Glu60X	2	0	0	0	2 (0.2)
p.Tyr577X	-	2	-	-	2 (0.2)
R709X; c.2125C>T/ p.Arg709X	0	0	2	0	2 (0.2)
W846X c.2537G>A / p.Trp846X	0	2	0	0	2 (0.2)
1154insTC; c.1021_1022dupTC / p.Phe342HisfsX28	1	0	0	0	1 (0.1)
1677delTA c.1545_1546delTA /p.Tyr515X	1	0	0	0	1 (0.1)
1898+1G>A c.1766+1G>A	1	0	0	0	1 (0.1)
2183AA>G c.2051_2052delAAinsG /p.Lys684SerfsX38	1	0	0	0	1 (0.1)
394delTT; c.262_263delTT / p.Leu881lefsX22	1	0	0	0	1 (0.1)
405+1G->A; c.273+1G>A	1	-	-	-	1 (0.1)
711+1G>T c.579+1G>T	0	1	0	0	1 (0.1)
c.1520_1522delTCT/p.Phe508del	1	-	-	-	1 (0.1)
c.1680-886A>G	1	-	-	-	1 (0.1)
c.1802T>C; p.Ile601Thr	-	-	-	1	1 (0.1)
c.2788G>T	-	1	-	-	1 (0.1)
c.3454G>C p.Asp1152His	1	-	-	-	1 (0.1)
c.473G>A / p.Ser158Asn	-	1	-	-	1 (0.1)
E585X; c.1753G>T / p.Glu585X	1	-	-	-	1 (0.1)
G576A; c.1727G>C / p.Gly576Ala	1	-	-	-	1 (0.1)
Gly1173GlnfsX21	-	2	-	-	1 (0.1)
I502T; c.1505T>C / p.Ile502Thr	0	0	0	1	1 (0.1)
I507del; c.1519_1521delATC /p.Ile507del	1	0	0	0	1 (0.1)
L206W; c.617T>G / p.Leu206Trp	1	-	-	-	1 (0.1)
large deletion exon 16-20	1	-	-	-	1 (0.1)
p.Gly458Val	-	-	1	-	1 (0.1)
Q493X, p.Gln493X, c.1477C>T	1	-	-	-	1 (0.1)
R117H c.350G>A / p.Arg117His	1	0	0	0	1 (0.1)
R31L; c.92G>T / p.Arg31Leu	1	-	-	-	1 (0.1)
R352Q; c.1055G>A / p.Arg352Gln	1	-	-	-	1 (0.1)
R7758X	-	1	-	-	1 (0.1)
R792X; c.2374C>T/ p.Arg792X	-	-	1	-	1 (0.1)
S1251N c.3752G>A / p.Ser1251Asn	0	1	0	0	1 (0.1)
S1255P; c.3763T>C / p.Ser1255Pro	-	-	1	-	1 (0.1)
S466X; c.1397C>A / p.Ser466X	-	-	1	-	1 (0.1)



S945L; c.2834C>T / p.Ser945Leu	-	-	1	-	1 (0.1)
Ser158IlefsX2	-	1	-	-	1 (0.1)
Ser877PhefsX29	-	1	-	-	1 (0.1)
V456A; c.1367T>C / p.Val456Ala	1	-	-	-	1 (0.1)
W679; c.2037G>A / p.Trp679X	1	-	-	-	1 (0.1)
Total	46 (7.3)	22 (12.6)	8 (9.8)	5 (62.5)	81 (9.1)

Supplementary Table 3: Univariable model results - factors for severe lung disease in children  $\geq 6$  years and adults in the SA CF registry, 2018

Factor	Level	n	Odds Ratio (95% CI)	Unadjusted p-value	Adjusted p-value
Sex	Male (Ref: Female)	292	1.33 (0.82,2.18)	0.249	1
Current age (units: 10-years)	Present (Ref: No)	292	1.99 (1.55,2.54)	<0.001	<0.001
Age diagnosis (units: 10-years)	Present (Ref: No)	285	1.26 (0.90,1.76)	0.18	1
p.Phe508del	Homozygous (Ref: Neither)	292	0.77 (0.37,1.57)	0.069	1
	Heterozygous (Ref: Neither)	292	1.45 (0.70,3.01)		
3120+1G>A; c.2988+1G>A homozygous/heterozygous	Present (Ref: No)	292	0.88 (0.40,1.92)	0.737	1
Caucasian	Present (Ref: other ancestry)	292	1.50 (0.83,2.72)	0.171	1
Pancreatic insufficient	Present (Ref: No)	290	1.54 (0.69,3.41)	0.279	1
Neonatal bowel obstruction	Present (Ref: No)	275	0.58 (0.28,1.19)	0.126	1
Household cigarette smoke	Present (Ref: No)	292	0.62 (0.30,1.28)	0.181	1
Informal housing with no water or electricity	Present (Ref: No)	292	2.05 (0.13,33.17)	0.616	1
Receiving social welfare grant	Present (Ref: No)	292	1.38 (0.72,2.65)	0.331	1
Private health insurance	Present (Ref: No)	292	0.83 (0.51,1.37)	0.467	1
Ever had <i>P.aeruginosa</i>	Present (Ref: No)	279	4.36 (1.65,11.49)	0.001	0.013
Time since first <i>P.aeruginosa</i> isolate (per 10-year interval) <sup>†</sup>	Present (Ref: No)	133	2.12 (1.38,3.25)	<0.001	0.007
Chronic <i>P.aeruginosa</i>	Present (Ref: No)	201	3.81 (2.08,6.95)	<0.001	<0.001
Chronic MSSA	Present (Ref: No)	200	0.57 (0.30,1.10)	0.089	1
Ever had MRSA	Present (Ref: No)	261	2.46 (0.98,6.18)	0.055	1
Chronic MRSA	Present (Ref: No)	198	8.88 (1.89,41.73)	0.001	0.024
Chronic <i>B. cepacia</i>	Present (Ref: No)	198	1.62 (0.50,5.22)	0.421	1
Chronic <i>aspergillus spp</i>	Present (Ref: No)	201	0.79 (0.34,1.88)	0.597	1
Another fungus/mould	Present (Ref: No)	292	2.19 (1.22,3.93)	0.009	0.187
Ever had <i>Achromobacter</i>	Present (Ref: No)	263	1.66 (0.54,5.11)	0.378	1
Ever had <i>Stenotrophomonas</i>	Present (Ref: No)	262	0.52 (0.16,1.61)	0.232	1
CF-related diabetes	Present (Ref: No)	286	3.79 (2.10,6.84)	<0.001	<0.001
ABPA	Present (Ref: No)	261	0.29 (0.06,1.30)	0.064	1
CF-liver disease	Yes, without cirrhosis (Ref: No)	282	1.02 (0.53,1.94)	0.073	1
	Yes, with cirrhosis (Ref: No)	282	2.87 (1.15,7.14)		
WAZ < -1.0 at diagnosis	Present (Ref: $\geq -1$ )	179	1.42 (0.66,3.08)	0.362	1
Undernutrition <sup>#</sup>	Present (Ref: No)	292	3.17 (1.80,5.61)	<0.001	0.002

Legend Supplementary Table 3:

† Included as an interaction term, to apply only to those who have had ever had *P.aeruginosa*

‡ Undernutrition includes: WHZ < -1.0, < 2 years age; BMIz < -1.0, 2-17 years; or BMI < 18.5 kg/m<sup>2</sup>, ≥ 18 years

Severe lung disease: FEV<sub>1z</sub> < -3 in children ≥ 6 years

Chronic *H.Influenzae*, any non-tuberculosis mycobacteria isolated, any mycobacterium tuberculosis and pneumothorax showed extreme OR estimates and extremely wide CIs, arising from very small samples and were excluded from univariable analysis.

ABPA: allergic bronchopulmonary aspergillosis

MSSA: methicillin sensitive *S. aureus*

MRSA: methicillin resistant *S. aureus*

Supplementary Table 4: Univariable model results – factors for undernutrition in children and adults in the SA CF registry, 2018

Factor	Level	n	Odds Ratio (95% CI)	Unadjusted p-value	Adjusted p-value
Sex	Male (Ref: Female)	398	0.97 (0.61,1.55)	0.9	1
p.Phe508del	Homozygous (Ref: Neither)	398	0.50 (0.27,0.92)	0.043	0.941
	Heterozygous (Ref: Neither)	398	0.85 (0.46,1.58)		
3120+1G>A; c.2988+1G>A homozygous/heterozygous	Present (Ref: No)	398	2.55 (1.42,4.58)	0.002	0.057
Ever had <i>P.aeruginosa</i>	Present (Ref: No)	385	1.24 (0.67,2.27)	0.486	1
Caucasian	Present (Ref: other ancestry)	398	0.35 (0.22,0.57)	<0.001	0.001
Pancreatic insufficient	Present (Ref: No)	396	1.28 (0.57,2.88)	0.54	1
Neonatal bowel obstruction	Present (Ref: No)	380	0.83 (0.43,1.62)	0.586	1
Household cigarette smoke	Present (Ref: No)	398	0.95 (0.49,1.84)	0.869	1
Informal housing with no water or electricity	Present (Ref: No)	398	1.36 (0.26,7.12)	0.724	1
Receiving social welfare grant	Present (Ref: No)	398	2.99 (1.70,5.25)	<0.001	0.005
Private health insurance	Present (Ref: No)	398	0.46 (0.28,0.73)	0.001	0.027
Chronic <i>P.aeruginosa</i>	Present (Ref: No)	256	1.76 (1.00,3.12)	0.05	1
Chronic MSSA	Present (Ref: No)	255	1.17 (0.64,2.17)	0.61	1
Ever had MRSA	Present (Ref: No)	351	1.86 (0.80,4.35)	0.165	1
Chronic MRSA	Present (Ref: No)	255	2.31 (0.77,6.94)	0.145	1
Chronic <i>B. cepacia</i>	Present (Ref: No)	254	1.80 (0.57,5.72)	0.328	1
Chronic <i>aspergillus spp</i>	Present (Ref: No)	258	1.49 (0.64,3.50)	0.368	1
Another fungus/mould	Present (Ref: No)	398	0.91 (0.50,1.65)	0.749	1
Ever had <i>Achromobacter</i>	Present (Ref: No)	353	0.91 (0.25,3.35)	0.89	1
Ever had <i>Stenotrophomonas</i>	Present (Ref: No)	353	0.83 (0.27,2.56)	0.743	1
CF-related diabetes	Present (Ref: No)	391	0.98 (0.51,1.87)	0.948	1
ABPA	Present (Ref: No)	361	1.53 (0.52,4.54)	0.455	1
WAZ < -1.0 at diagnosis	Present (Ref: ≥ -1))	270	2.18 (1.07,4.44)	0.024	0.558
CF-liver disease	Yes, without cirrhosis (Ref: No)	386	0.99 (0.52,1.88)	0.504	1
	Yes, with cirrhosis (Ref: No)	386	0.50 (0.14,1.75)		
Current age (units: 10-years)	Present (Ref: No)	398	0.82 (0.66,1.01)	0.062	1
Age diagnosis (units: 10-years)	Present (Ref: No)	391	1.12 (0.80,1.59)	0.519	1
Time since first <i>P.aeruginosa</i> isolate (per 10-year interval)†	Present (Ref: No)	188	0.83 (0.56,1.23)	0.348	1

Legend Supplementary Table 4:

† Included as an interaction term, to apply only to those who have had ever had *P.aeruginosa*

‡ Undernutrition includes: WHZ < -1.0, < 2 years age; BMIz < -1.0, 2-17 years; or BMI < 18.5 kg/m<sup>2</sup>, ≥ 18 years

Chronic H.Influenzae, any non-tuberculosis mycobacteria isolated, any mycobacterium tuberculosis and pneumothorax showed extreme OR estimates and extremely wide CIs, arising from very small samples and were excluded from univariable analysis

Severe lung disease: FEV<sub>1</sub>z < -3 in children ≥ 6 years

ABPA: allergic bronchopulmonary aspergillosis

MSSA: methicillin sensitive *S. aureus*

MRSA: methicillin resistant *S. aureus*